Concepedia

Publication | Closed Access

A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer

DOI

31

Citations

18

References

2004

Year

Jean-­Marc Ferrero, Cyril Foa, Simon Thézenas, Philippe Ronchin, Frédéric Peyrade, B. Valenza, G Lesbats, G Garnier, J.L. Boublil, X. Tchiknavorian,
Oncology

Abstract

Weekly docetaxel at a dosage of 40 mg/m(2) is a well-tolerated treatment, which has very promising activity on the reduction of PSA in metastatic HRPC. A large phase III study is underway.

References

YearCitations

Page 1